Every tumour sequencing report lists open, nearby, matched trials pulled live
The report that tells a patient their tumour's mutations should also tell them which trials are recruiting for those mutations within reach, with the status checked that week rather than copied from a stale list.
Genomic testing laboratories would embed a matching step at report generation: variants are mapped to trial arms (OncoKB and CIViC annotations, ClinicalTrials.gov structured eligibility), filtered by geography and current recruiting status confirmed by direct query, and listed with a contact. Some commercial reports do this partly; the idea makes live status confirmation and geography the standard, with the same section in public-lab reports.
- Trials enrol too few, too slowly · Fewer than one in ten adults with cancer joins a trial. Trials close for lack of patients, not lack of ideas.
- Knowledge reaches practice too slowly · Knowledge diffusion is slow: it takes years for a proven result to change what most patients receive, and no one can keep up with the literature.
Pages like this
not linked directly; found by shared links- IdeaEvery tumour genomic report machine-readable and deposited nationally
Shares Caris Life Sciences, CIViC, OncoKB, Next-generation sequencing (NGS).
- IdeaLabel every targetable mutation as truncal or branch on the report
Shares Next-generation sequencing (NGS), Foundation Medicine (Roche), Guardant Health, Tempus AI.
- TechnologyCancer variant knowledgebases and molecular tumour boards
Shares CIViC, OncoKB, AI trial matching & clinical decision support, Comprehensive genomic profiling.
- IdeaDrop mandatory fresh biopsies where blood or archival tissue would do
Shares Foundation Medicine (Roche), Guardant Health, Trials enrol too few, too slowly, Comprehensive genomic profiling.
- IdeaTrial matching inside the electronic record at the moment a treatment is chosen
Shares Tempus AI, AI trial matching & clinical decision support, ClinicalTrials.gov, Trials enrol too few, too slowly.
- IdeaLabel every biomarker claim with an evidence phase, like drugs
Shares CIViC, OncoKB, Knowledge reaches practice too slowly.
- IdeaAn open knowledge graph linking trials, results, biomarkers, drugs and recommendations
Shares CIViC, OncoKB, ClinicalTrials.gov, Knowledge reaches practice too slowly.
- IdeaA single calibrated tumour mutational burden across all sequencing panels
Shares Next-generation sequencing (NGS), Foundation Medicine (Roche), Tempus AI.